1 items1 sources1 stocks
Yahoo Finance-Jul 15, 09:01 PM
Johnson & Johnson Q2 2026 Earnings: Strong Sales Growth, Raised Full-Year Guidance
Johnson & Johnson reported Q2 2026 worldwide sales of $25.3 billion, up 5.6% operationally, with adjusted diluted EPS of $2.90 (up 4.7% YoY) despite a 55.7% STELARA decline from biosimilar competition. The company raised its full-year 2026 guidance, now expecting operational sales growth of 6.5% to 7.1% and adjusted EPS of $11.50 to $11.65, with full-year free cash flow approaching $21 billion.
Why it matters: Innovative Medicine sales grew 6.8% to $16.4 billion driven by oncology, immunology, and neuroscience, while MedTech sales rose 3.6% to $8.9 billion despite cardiovascular headwinds.